Immunome (IMNM) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Company vision and strategy

• Built a large pipeline by merging chemistry-focused and antibody-focused entities within 10 months.

• Focused on targeted oncology, especially antibody-drug conjugates (ADCs) with novel targets.

• Completed seven business development deals in ten months, acquiring assets from various companies.

• Plans to introduce two novel ADCs into the clinic annually, aiming for a robust clinical pipeline.

• Maintains a strong cash position, supporting operations into early or mid-2026.

ADC development and innovation

• Prioritizes novel targets over established ones to differentiate in the ADC space.

• Emphasizes the importance of therapeutic window and rapid antibody internalization for ADC efficacy.

• Utilizes high-throughput screening to select optimal antibodies for ADCs.

• Plans to file IND for ROR1 ADC in Q1 2025, with potential for initial clinical data in 2025.

• Cautious about disclosing novel targets to protect intellectual property.

Lead programs and clinical timelines

• Lead program AL102, a gamma secretase inhibitor, is in a fully enrolled Phase 3 trial for desmoid tumors.

• Phase 3 unblinding for AL102 expected in the second half of 2025.

• ROR1 ADC will target both liquid and solid tumors, with initial focus on liquid tumors and a basket approach for solid tumors.

• IND submission for FAP-targeted radioligand therapy planned for Q1 2025.